Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients

Journal of Heart and Lung Transplantation

Volumn 33, Issue 5, 2014, Pages 499-506

  Singh, Neha ^a   Jacobs, Frank ^a   Rader, Daniel J ^b   Vanhaecke, Johan ^c   Van Cleemput, Johan ^c   De Geest, Bart ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cardiac allograft vasculopathy; cholesterol efflux; endothelial progenitor cell; HDL function; heart transplantation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; CYCLOSPORIN; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ACUTE GRAFT REJECTION; ADULT; ANGIOCARDIOGRAPHY; ANIMAL CELL; ARTICLE; BODY MASS; CARDIAC ALLOGRAFT VASCULOPATHY; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOLIPEMIA; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; SMOKING; STEROID THERAPY; ALLOGRAFT; ANIMAL; BLOOD; C57BL MOUSE; CROSS-SECTIONAL STUDY; DISEASE MODEL; FOLLOW UP; GRAFT REJECTION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TIME;

ALLOGRAFTS; ANIMALS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL PROGENITOR CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROGNOSIS; TIME FACTORS;

EID: 84898835520     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2014.01.859     Document Type: Article

References (29)

1. D. Schmauss, and M. Weis Cardiac allograft vasculopathy: recent developments Circulation 117 2008 2131 2141
2. M. Rahmani, R.P. Cruz, and D.J. Granville et al. Allograft vasculopathy versus atherosclerosis Circ Res 99 2006 801 815
3. J. Parameshwar, J. Foote, and L. Sharples et al. Lipids, lipoprotein (a) and coronary artery disease in patients following cardiac transplantation Transpl Int 9 1996 481 485
4. H. Valantine, P. Rickenbacker, and M. Kemna et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study Circulation 103 2001 2144 2152
5. G.E. Cooke, G.M. Eaton, and G. Whitby et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients J Am Coll Cardiol 36 2000 509 516
6. J.M. Sanchez-Gomez, L. Martinez-Dolz, and I. Sanchez-Lazaro et al. Influence of metabolic syndrome on development of cardiac allograft vasculopathy in the transplanted heart Transplantation 93 2012 106 111
7. T. McLaughlin, F. Abbasi, and K. Cheal et al. Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Med 139 2003 802 809
8. O. Biadi, L. Potena, and W.F. Fearon et al. Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation J Heart Lung Transplant 26 2007 324 330
9. E.R. Raichlin, J.P. McConnell, and A. Lerman et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy J Heart Lung Transplant 26 2007 826 833
10. V. Atger, T. Leclerc, and M. Cambillau et al. Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity Atherosclerosis 103 1993 29 41
11. D. Sviridov, J. Chin-Dusting, and P. Nestel et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport Transplantation 81 2006 361 366
12. J.S. Stamler, D.E. Vaughan, and J. Loscalzo Immunosuppressive therapy and lipoprotein abnormalities after cardiac transplantation Am J Cardiol 68 1991 389 391
13. S. Yamashita, K. Tsubakio-Yamamoto, and T. Ohama et al. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions J Atheroscler Thromb 17 2010 436 451
14. E.A. Fisher, J.E. Feig, and B. Hewing et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport Arterioscler Thromb Vasc Biol 32 2012 2813 2820
15. A.V. Khera, M. Cuchel, and M. de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
16. G. Vassalli, A. Gallino, and M. Weis et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur Heart J 24 2003 1180 1188
17. D.M. Smadja, I. Bieche, and G. Uzan et al. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system Arterioscler Thromb Vasc Biol 25 2005 2321 2327
18. Y. Feng, F. Jacobs, and E. van Craeyveld et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells Arterioscler Thromb Vasc Biol 28 2008 278 283
19. N. Singh, E. van Craeyveld, and M. Tjwa et al. Circulating apoptotic endothelial cells and apoptotic endothelial microparticles independently predict the presence of cardiac allograft vasculopathy J Am Coll Cardiol 60 2012 324 331
20. M.R. Mehra, M.G. Crespo-Leiro, and A. Dipchand et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy - 2010 J Heart Lung Transplant 29 2010 717 727
21. B.F. Asztalos, M. de la Llera-Moya, and G.E. Dallal et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux J Lipid Res 46 2005 2246 2253
22. A.V. Khera, M. Cuchel, and M. de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
23. S. van Linthout, D. Collen, and B. De Geest Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I Hum Gene Ther 13 2002 829 840
24. A. Ferrara, E. Barrett-Connor, and L.D.L. Shan J. Total and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994 Circulation 96 1997 37 43
25. E. Di Angelantonio, N. Sarwar, and P. Perry et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
26. W. Annema, and A. von Eckardstein High-density lipoproteins. multifunctional but vulnerable protections from atherosclerosis Circ J 77 2013 2432 2448
27. M. de la Llera-Moya, D. Drazul-Schrader, and B.F. Asztalos et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler Thromb Vasc Biol 30 2010 796 801
28. H. Zhou, K.C. Tan, and S.W. Shiu et al. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy Diabetes Metab Res Rev 24 2008 617 623
29. P.M. O'Connor, B.R. Zysow, and S.A. Schoenhaus et al. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender J Lipid Res 39 1998 670 678